Steigerwald Gordon & Koch Inc. reduced its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.3% in the 1st quarter, HoldingsChannel reports. The fund owned 55,480 shares of the medical research company’s stock after selling 753 shares during the period. Amgen makes up approximately 2.8% of Steigerwald Gordon & Koch Inc.’s portfolio, making the stock its 15th largest position. Steigerwald Gordon & Koch Inc.’s holdings in Amgen were worth $10,540,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the company. Ruggie Capital Group grew its stake in shares of Amgen by 297.1% in the fourth quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after buying an additional 101 shares in the last quarter. Capital Financial Planning LLC bought a new position in shares of Amgen in the fourth quarter valued at $27,000. Massey Quick Simon & CO. LLC grew its stake in shares of Amgen by 710.5% in the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after buying an additional 135 shares in the last quarter. Next Capital Management LLC bought a new position in shares of Amgen in the fourth quarter valued at $33,000. Finally, Essex Investment Management Co. LLC bought a new position in shares of Amgen in the fourth quarter valued at $39,000. 78.01% of the stock is owned by institutional investors.
Several equities analysts recently weighed in on the stock. Zacks Investment Research cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 23rd. Oppenheimer set a $224.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research report on Sunday, January 27th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $190.00 price objective on shares of Amgen in a research report on Wednesday, January 30th. Leerink Swann reduced their price objective on shares of Amgen from $200.00 to $192.00 and set a “market perform” rating for the company in a research report on Wednesday, January 30th. Finally, Mizuho set a $208.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research report on Friday, April 12th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $209.05.
In other news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $175.73, for a total transaction of $351,460.00. Following the completion of the sale, the director now owns 15,092 shares of the company’s stock, valued at $2,652,117.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 6,000 shares of company stock valued at $1,115,580 in the last three months. Insiders own 0.25% of the company’s stock.
Shares of AMGN traded up $1.17 during midday trading on Thursday, reaching $172.47. 74,760 shares of the stock were exchanged, compared to its average volume of 2,956,760. Amgen, Inc. has a twelve month low of $166.30 and a twelve month high of $210.19. The company has a debt-to-equity ratio of 2.71, a quick ratio of 2.53 and a current ratio of 2.77. The company has a market capitalization of $103.50 billion, a P/E ratio of 11.90, a P/E/G ratio of 2.24 and a beta of 1.15.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, April 30th. The medical research company reported $3.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.45 by $0.11. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The company had revenue of $5.56 billion during the quarter, compared to the consensus estimate of $5.55 billion. During the same quarter last year, the firm earned $3.47 earnings per share. The company’s revenue was up .1% on a year-over-year basis. On average, equities research analysts predict that Amgen, Inc. will post 13.94 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $1.45 per share. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.36%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is currently 40.28%.
ILLEGAL ACTIVITY WARNING: “Steigerwald Gordon & Koch Inc. Decreases Stake in Amgen, Inc. (AMGN)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2019/05/23/steigerwald-gordon-koch-inc-decreases-stake-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: What is the Quick Ratio?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.